GlassScriptPhysician profile
Robert G Shoss
NPI 1710918255
$29,827.01
in general payments reported to CMS, 2019-2025
31 companies · $5,748 in 2025
The $5,748 reported for 2025 was more than what 90% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,757 · 2020: $1,608 · 2021: $3,381 · 2022: $1,964 · 2023: $3,258 · 2024: $5,110 · 2025: $5,748.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $323.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,793.40 |
| Education | $323.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $10,732.68 | 2019-2025 | |
| Abbvie INC. | $4,239.94 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $3,773.13 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $1,585.91 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $1,231.03 | 2019-2025 | Siliq, Duobrii, Cabtreo |
| Incyte Corporation | $1,151.94 | 2022-2025 | Opzelura, Opzelura |
| Sun Pharmaceutical Industries INC. | $1,010.43 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Ucb, INC. | $926.69 | 2019-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $877.50 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Regeneron Healthcare Solutions, INC. | $657.96 | 2019-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $465.60 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $459.69 | 2022-2025 | Sotyktu |
| Leo Pharma INC. | $408.79 | 2022-2025 | Adbry |
| Janssen Scientific Affairs, LLC | $403.52 | 2019-2022 | |
| Galderma Laboratories, L.P. | $401.36 | 2020-2025 | Nemluvio, Aklief |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $366.83 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $287.31 | 2022-2024 | Vtama |
| Amgen INC. | $190.81 | 2022-2025 | Otezla, Otezla |
| Merz North America, INC. | $157.82 | 2023 | Xeomin |
| Celgene Corporation | $138.91 | 2019 | |
| Sanofi-Aventis U.S. LLC | $96.99 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.26 | 2023-2024 | Spevigo |
| Biofrontera INC. | $41.27 | 2025 | Ameluz |
| Organon LLC | $32.78 | 2024 | |
| Alexion Pharmaceuticals, INC. | $27.24 | 2025 | Koselugo |
| Paratek Pharmaceuticals, INC. | $23.31 | 2024 | Nuzyra |
| Mission Pharmacal Company | $23.03 | 2019 | |
| Kyowa Kirin, INC. | $19.70 | 2024 | Poteligeo |
| Helsinn Therapeutics (U.S.), INC. | $18.81 | 2025 | Valchlor |
| Prugen, INC. Pharmaceuticals | $17.29 | 2019 | |
| Allergan, INC. | $16.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Shoss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.